A proposed class action in Northern California alleges Oura overstated sleep-stage accuracy in its marketing.
Why it matters: The case could test how far wearable makers can go in marketing sleep and wellness features. It may also shape how consumers, regulators and plaintiffs’ lawyers evaluate validation claims for smart rings.
- Clarkson Law Firm filed the proposed class action in U.S. District Court for the Northern District of California.
- TechCrunch reported the complaint alleges Oura promoted its rings as "built for accuracy" and cited sleep-staging accuracy figures of 79% and later 95%.
- Bloomberg Law reported the suit also accuses Oura of falsely advertising its rings as able to track the quality of a wearer's sleep cycles.
- The lawsuit seeks to stop the challenged advertising and win restitution for buyers.
A proposed class action filed in the U.S. District Court for the Northern District of California alleges Oura misled consumers about the accuracy of its sleep-tracking and sleep-stage detection claims. TechCrunch reported the filing was brought by Clarkson Law Firm in San Francisco.
According to the complaint as described by TechCrunch, Oura told consumers its rings were "built for accuracy" and cited sleep-staging figures of 79% and later 95% versus clinical sleep labs. The complaint also alleges the product does not directly measure the physiological signals needed to assess sleep quality or identify sleep stages, instead relying on AI-generated estimates.
A separate Bloomberg Law report said the suit accuses Oura of falsely advertising its rings as able to track the quality of a wearer's sleep cycles. The complaint seeks injunctive relief and restitution for consumers who bought the product based on the claims.
Oura's support materials say sleep staging uses biosignals including movement, skin temperature, resting heart rate, heart rate variability and respiratory rate, and that sleep staging requires continuous data. The company also says the ring cannot diagnose sleep apnea and that some conditions can affect accuracy. Oura's sleep stages page and medical-conditions page outline those limits.
The FDA says whether a wearable is a medical device depends on its intended use and claims, and its digital-health guidance includes wearables such as smart rings when they are marketed for medical use. FDA guidance and digital-health guidance show why marketing language around sleep can matter.
By the numbers
- 79% - the sleep-staging accuracy figure the complaint says Oura previously cited.
- 95% - the later sleep-staging accuracy figure the complaint says Oura cited versus clinical sleep labs.
Yes, but: Oura's own documentation says sleep-staging uses multiple biosignals and notes limits on accuracy, which the company can point to in defending its claims.
What's next: The proposed class action will move through the normal motions process unless the parties settle or the court dismisses it.